Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (292)	9/1/1999 12:51:00 AM
From: Bharat H. Barai	Read Replies (1) \| Respond to of 666

The response rates to Bexxar are just great. If the data from initial trials hold good, the drug may even replace chemotherapy or be used routinely with chemotherapy. I am amazed at the beating that Coulter stock has taken on such a minor issue. Ignoring the fundamentals and respecting the charts and analysts is dangerous. As a Hematologist, last year I decided to buy Idec after seeing what Rituxan was worth. When I read on SI about how the chart looked terrible for Idec, I sidelined my Medical knowledge and fundamentals and did not buy the stock in 20s. Today it is trading around 130, 15 months later. I feel that CLTR stocks will recover very rapidly and could trade around 100 in 2 years. The drug is just superb and its merits and fundamentals will catch up with technicians and analysts. Those who who will have courage of convictions and respecting the fundamentals of a product or a company will be richly rewarded. Bharat H. Barai MD Hematologist-Oncologist

To: Vector1 who wrote (292)	11/15/1999 11:52:00 PM
From: Bob L	Read Replies (1) \| Respond to of 666

According to a Piper Jaffry report, at the recent Chemotherapy Foundation Symposium in New York, some preliminary results of the bexxar/fludarabine study were presented. All evaluable patients (there were 40 in the study) have responded to the combination. Importantly, no HAMA (human anti-mouse antibody) responses were observed. Proving once again that Vector1 has a nose for the news on this topic. Unfortunately, SmithKline announced in a conference call last month that refiling of the BLA will be end of first quarter 2000, which I don't think has been posted here before. Anyone hear this call?